By Chris Wack
ADMA Biologics shares were 15% higher, at $25.25, after the company said the Food and Drug Administration approved its innovative yield-enhancement production process.
The shares hit their 52-week high of $25.67 earlier in the sesison, and are up 278% in the past 12 months.
The biopharmaceutical company said this process has demonstrated an ability to increase production yields by 20% from the same starting plasma volume.
ADMA Biologics makes products that start out as donated plasma. From the plasma donations, the company extracts immunoglobulin, or antibodies, capable of blocking specific viruses. Its products infuse people with primary immunodeficiency with the virus-blocking antibodies their own bodies can't make.
The company expects the FDA's approval to speed up its revenue and earnings trajectory, beginning later this year.
ADMA says the new yield process will benefit its Bivigam and Asceniv antibody products.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 28, 2025 09:58 ET (13:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。